* Acorda Therapeutics Inc-presents data from clinical and
preclinical trials of CVT-301 for treatment of OFF periods in
Parkinson’s disease
The post BRIEF-Acorda Therapeutics presents data from clinical and preclinical trials of CVT-301 appeared first on NASDAQ.